Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis. [PDF]
Shadman M +10 more
europepmc +1 more source
Current and future landscape of Bruton tyrosine kinase inhibitors in allergy. [PDF]
Lin EV +3 more
europepmc +1 more source
Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials. [PDF]
Mahadevia H, Ponvilawan B, Shrestha A.
europepmc +1 more source
Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia. [PDF]
Hays P.
europepmc +1 more source
Real-world overall survival comparison between first-line Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia/small lymphocytic lymphoma: An analysis of Veterans Health Administration data. [PDF]
Fitzgerald L +13 more
europepmc +1 more source
Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction. [PDF]
Lin C +5 more
europepmc +1 more source
Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)-an analysis of an administrative health claims database. [PDF]
Vallabhaneni S +5 more
europepmc +1 more source
Cardiovascular toxicity of Bruton tyrosine kinase inhibitors: forget about selectivity but watch the clock. [PDF]
Minotti G.
europepmc +1 more source
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study. [PDF]
Ghosh N +32 more
europepmc +1 more source
Navigating the complex terrain of hepatitis B virus reactivation in the era of Bruton tyrosine kinase inhibitors. [PDF]
Liu WN, Dai MS, Lin F, Lin GM.
europepmc +1 more source

